Approvable letter for Zelapar

AMRN said the FDA issued an approvable letter for Zelapar selegiline, a MAO-B inhibitor, as an adjunct to levadopa to treat Parkinson's disease (PD). AMRN has an exclusive option to acquire the U.S. r...